Advocacy Wealth Management Services’s CytomX Therapeutics CTMX Stock Holding History

Advocacy Wealth Management Services’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	-$2K	–	142
2018 Q4	$2K	Hold	100	–	–	﹤0.01%	154
2018 Q3	$2K	Hold	100	–	–	﹤0.01%	168
2018 Q2	$2K	Hold	100	–	–	﹤0.01%	167
2018 Q1	$3K	Hold	100	–	–	﹤0.01%	187
2017 Q4	$2K	Hold	100	–	–	﹤0.01%	206
2017 Q3	$2K	Hold	100	–	–	﹤0.01%	259
2017 Q2	$2K	Hold	100	–	–	﹤0.01%	262
2017 Q1	$2K	Buy	+100	New	+$1.32K	﹤0.01%	287

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Advocacy Wealth Management Services's CTMX Position: Q1 2019 in Review

Advocacy Wealth Management Services sold out of CytomX Therapeutics (CTMX) in Q1 2019, closing a stake of 100 shares — an estimated $2K sold.

Advocacy Wealth Management Services first reported a position in CTMX in Q1 2017 and held it in 8 quarters. The position peaked at $3K in Q1 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

Advocacy Wealth Management Services reported no remaining CytomX Therapeutics position as of Q1 2019 after selling out during the quarter.
Advocacy Wealth Management Services sold 100 CytomX Therapeutics shares in Q1 2019, an estimated $2K.
Advocacy Wealth Management Services first reported a position in CytomX Therapeutics in Q1 2017 and held it in 8 quarters.
Advocacy Wealth Management Services's CytomX Therapeutics position peaked at $3K in Q1 2018.
113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on Advocacy Wealth Management Services's 13F filing for Q1 2019, filed 2 Apr 2019.